Michael Wang
Post-doctoral Researcher
Research interests
Epstein-Barr virus (EBV) is present in most nasopharyngeal cancer cases, about 8% of gastric cancer cases, and in a multitude of lymphomas. As such, developing therapeutic strategies that target EBV in these cancers would have broad applications. My research focuses on developing T-cell based therapies that target novel EBV antigens, as well as combination therapies that boost the potencies of said T-cell therapies. Furthermore, I am also interested in the research and development of T-cell engagers and non-conventional T-cell therapies.
Background
I obtained my Bachelor’s Degree in Biomedical Sciences (Hons) at the University of Hong Kong in 2022. Between 2022 and 2026, I joined Prof. Xiao-Ning Xu’s lab at Imperial College London as a PhD student, during which I also joined Prof. Xin Lu’s lab as a visiting student. My doctoral research focused on developing TCR-T and CAR-T therapies against the EBV Zta protein and characterizing them using in-vitro models.